Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT03799601
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-01-03
- Target Recruit Count
- 44
- Registration Number
- NCT03792542
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2019-10-22
- Target Recruit Count
- 83
- Registration Number
- NCT03769805
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jangsu, China
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2018-12-11
- Target Recruit Count
- 40
- Registration Number
- NCT03766776
Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-04-03
- Target Recruit Count
- 103
- Registration Number
- NCT03755869
- Locations
- 🇨🇳
Shaanxi Provincial Cancer Hospital, Xian, Shanxi, China
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Anhui Shi, MD
- Target Recruit Count
- 90
- Registration Number
- NCT03743129
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 43
- Registration Number
- NCT03732846
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2018-11-02
- Target Recruit Count
- 38
- Registration Number
- NCT03728374
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03720873
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 25
- Registration Number
- NCT03672136
- Locations
- 🇨🇳
SHANDONG Cancer Hospital and Institute, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.